Search for other papers by Lars Bastholt in
Google Scholar
PubMed
Department of Nuclear Medicine, University Hospital Würzburg, Würzburg
Search for other papers by Michael C. Kreissl in
Google Scholar
PubMed
Search for other papers by Dagmar Führer in
Google Scholar
PubMed
Search for other papers by Ana L. Maia in
Google Scholar
PubMed
Search for other papers by Laura D. Locati in
Google Scholar
PubMed
Search for other papers by Léa Maciel in
Google Scholar
PubMed
Search for other papers by Yi Wu in
Google Scholar
PubMed
Search for other papers by Kevin N. Heller in
Google Scholar
PubMed
Search for other papers by Alan Webster in
Google Scholar
PubMed
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
.gov No. NCT01298323). Patients were randomized 1:1 to either the experimental arm (inclusion in the patient outreach programme, referred to as ‘outreach') or the control arm (standard AE monitoring schedule, referred to as ‘vandetanib control') using an